KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $60.1 million.

  • Amneal Pharmaceuticals' Other Non-Current Assets rose 8.78% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 8.78%. This contributed to the annual value of $60.1 million for FY2024, which is 8.31% up from last year.
  • Amneal Pharmaceuticals' Other Non-Current Assets amounted to $60.1 million in FY2024, which was up 8.31% from $55.5 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Other Non-Current Assets ranged from a high of $103.2 million in FY2022 and a low of $20.6 million during FY2021.
  • Its 3-year average for Other Non-Current Assets is $73.0 million, with a median of $60.1 million in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Other Non-Current Assets plummeted by 49.53% in 2020 and then skyrocketed by 400.71% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $22.3 million in 2020, then decreased by 7.74% to $20.6 million in 2021, then skyrocketed by 400.71% to $103.2 million in 2022, then tumbled by 46.21% to $55.5 million in 2023, then increased by 8.31% to $60.1 million in 2024.